Table 1.
Clinical characteristics of the random sample of drugs included in our analysis (n = 47)
| Indication | n | Furthest stage of development (%) | FDA approval (%) | |
|---|---|---|---|---|
| Phase 2 | Phase 3 | |||
| Cancer | 19 | 9 (47%) | 9 (47%) | 5 (26%) |
| Cardiovascular | 9 | 3 (33%) | 5 (56%) | 2 (22%) |
| Infection | 9 | 2 (22%) | 7 (78%) | 3 (33%) |
| Neurological | 4 | 0 | 2 (50%) | 1 (25%) |
| Sepsis | 3 | 3 (100%) | 0 | 0 |
| Pain | 2 | 0 | 2 (100%) | 0 |
| Diabetes | 1 | 1 (100%) | 0 | 0 |
| Total | 47 | 18 (38%) | 25 (53%) | 11 (23%) |